Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

Portola Pharmaceuticals to Regain Global Rights for Investigational Medicine Betrixaban from Merck

By Pharmaceutical Processing | March 24, 2011

Portola Pharmaceuticals and Merck known as MSD outside the United States and Canada, today announced that Merck
plans to return to Portola all rights for betrixaban, an investigational oral
Factor Xa inhibitor anticoagulant being evaluated for the prevention of stroke
in patients with atrial fibrillation (SPAF). This decision was made following a
review of Merck’s investigational portfolio.

“Regaining full rights to betrixaban represents a
transformational opportunity for Portola,” said William Lis, chief
executive officer of Portola. “We will work with our academic partners on
options for an independent development plan to bring betrixaban to the market
and intend to discuss these options with the FDA in the near future.” In
July 2009, Merck and Portola announced an exclusive global collaboration and
license agreement for the development and commercialization of betrixaban.
Betrixaban most recently completed Phase II testing in the EXPLORE-Xa trial in
which it showed dose dependent clinical activity with similar or lower rates of
bleeding compared to warfarin in the study population. These results were presented
during a late-breaking clinical trials session at the American College
of Cardiology’s 59th Annual Scientific Session in March 2010.

“Working closely with our Portola collaborators we have
advanced betrixaban to this Phase III-ready stage,” said Luciano Rossetti,
M.D., senior vice president, Global Scientific Strategy at Merck. “As part
of an ongoing prioritization of our late-stage pipeline, we have decided to
return rights for betrixaban to Portola. Merck continues to advance its broad
late-stage pipeline and remains committed to delivering medicines for
cardiovascular disease.”   

Related Articles Read More >

Doctor, woman patient and tablet for consulting with results, medical info and talk for healthcare with mockup space. Japanese medic, digital touchscreen or show video for surgery, wellness or advice.
Putting patients first in clinical trials
Confidently navigate the transition from bench to batch
Merck
FDA approves Merck’s Winrevair to treat pulmonary arterial hypertension
kobayashi pharmaceutical logo
Report: Japan health authorities investigate Kobayashi Pharmaceutical factory after five deaths
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE